Research in Nottingham has indicated that serotonin plays an important role in controlling bowel function. Professor Robin Spiller and the Nottingham Digestive Diseases Biomedical Research Unit are currently doing a large multicentre trial (TRITON) looking at whether the serotonin receptor 3 antagonist, ondansetron can benefit patients with Irritable Bowel Syndrome and diarrhoea. They are interested to know how many patients are currently being treated with this product in primary care and how familiar primary care physicians are with its use.
Your response would be most helpful in guiding its subsequent introduction to primary care. Please note this survey is anonymous and only for healthcare professionals.